RO7284755 treatment in combination with anti-PD-L1 elicited efficacious antitumor immunity by promoting pre-existing stem-like and tumor-reactive CD8+ T cells and remodeling immunosuppressive tumor-associated macrophages [115]. This evidence concerns the gene CD8A and neoplasm.